Maravai LifeSciences

MRVI

Market cap $488M

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner  Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What's Happening: Bragar Eagel & Squire, P.C.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner  Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, Sept.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Company Participants Bernd Brust - CEO & Director Debra Hart - Senior Director of Investor Relations Rajesh J. Asarpota - EVP & Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Catherine Walden Ramsey Schulte - Robert W.

Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.

Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings

SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 financial and operating results after the market close on Monday, August 11, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders following a class action complaint that was filed against Maravai on March 3, 2025 with a Class Period from August 7, 2024 and February 24, 2025. Our investigation concerns whether the board of directors of Maravai have breached their fiduciary duties to the company.

SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating potential violations of federal and state securities laws by certain officers and directors of the following companies: Quantum Computing Inc. (NASDAQ: QUBT), AppLovin Corporation (NASDAQ: APP), Skyworks Solutions, Inc. (NASDAQ: SWKS), and Maravai LifeSciences Holdings Inc. (NASDAQ: MRVI). Current long-term shareholders of any of these companies that have continuously held shares during the relevant time periods, may be able to hold certain officers and directors personally accountable for misconduct and assist in reforming the company's corporate governance. To learn more, please see the summaries below.